2.Dr.Sherine Helmy_From Egypt to Thailand_Turning Hepatitis C Elimination into Reallity.pdf

1、From Egypt to Thailand:Turning Hepatitis C Elimination into RealityBangkok,January 15th 2026T Tr ri il la at te er ra al l S Sy ym mp po os si iu um m-WWH HO O G Ge en ne ev va aF Fe eb br ru ua ary ry 2 20 01 18 8S Se ep pt te em mb be er r 2 20 01 19 9Tai&Malaysian Gov.,DNDi&MPP“WeWe havhave e a a

2、 s strtrategicategic plplan.an.ItIt s s c callealled d dodoi ingng ththi ingngs.”s.”Herb Kelleher“Create a cause,not a business.Gary Hamel3030The journey of Hepatitis C in EgyptR AV I DA S V I R A G L O B A L C O L L A B O R AT I O N T O A D D R E S S P U B L I C H E A L T H N E E D S3131Updating RD

3、V statusDecember 20233232DNDi HCV Strategy,the way forwardU P D AT E R AV I D A S V I R S T AT U S-D E C E M B E R 2 0 2 3HCV Completion Plan:approved by DNDi-BoD and ongoing discussions for RDV strategic positioningoRDV inclusion in WHO TT guidelinesoResearch&DevelopmentoRegulatory&RegistrationDNDi

4、s strategy aims to increase the availability of affordable treatments in relevant LMICs using an end-to-end approach,leveraging the success of RDV.We deploy two complementary components:R&D and AccessoR&D component focuses on developing and support partners registering RDV as for chronic HCV used in

5、 combination with sofosbuvir.Target countries for RDV registration are those which lack access to affordable treatment,high GT3 prevalence and where use of sofosbuvir is not blocked by patents.oAccess component focuses on better access for HCV patients,through access to diagnosis and to affordable D

6、AAs.We do this by removing access barriers on demand,supply,financing and structural obstacles.Our activities target global level and country levels,prioritizing high burden countries.3333We developed ravidasvir for use as part of an effective,simple-to-use,affordable treatment for hepatitis C.We ar